Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Rating of “Buy” by Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have earned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $10.67.

AQST has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Lake Street Capital dropped their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $2.45 on Tuesday. The company’s fifty day moving average price is $2.75 and its 200-day moving average price is $3.32. The firm has a market capitalization of $243.35 million, a price-to-earnings ratio of -5.44 and a beta of 2.02. Aquestive Therapeutics has a one year low of $2.12 and a one year high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. As a group, equities research analysts expect that Aquestive Therapeutics will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Summit Wealth & Retirement Planning Inc. bought a new position in shares of Aquestive Therapeutics in the 1st quarter worth approximately $29,000. Victory Capital Management Inc. purchased a new stake in Aquestive Therapeutics in the first quarter worth about $31,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of Aquestive Therapeutics during the first quarter valued at approximately $33,000. New York State Common Retirement Fund lifted its holdings in shares of Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after purchasing an additional 10,700 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Aquestive Therapeutics in the 4th quarter worth approximately $44,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.